Table 1.

Numbers of Participants With Available Urinary N-Telopeptide (NTX) Measurement According to Year of Follow-up

	Visit numbera
	0 = baseline	1	2	3	4	5	6	7	8
Total no. of participants	3302	2881	2746	2710	2679	2577	2448	2368	2279
No. of participants for whom data were available regarding NTX, VMS,b and menopausal stage	2336	2043	1944	1830	1728	1610	1707	1663	1061
No. of participants after further censoring of women with hysterectomy, bilateral oophorectomy, pregnancy, breast-feeding, hormone therapy use, use of medication known to influence bone density, and missed visitsc	2283	1760	1521	1330	1199	1110	1147	1099	686

^aVisit number 0 denotes baseline visit.

^bVMS = vasomotor symptoms.

^cMedication known to influence bone density includes self-reported use of corticosteroid pills, medications for epilepsy, tamoxifen, chemotherapy, or medications used to prevent or treat osteoporosis. Women were censored at the first visit at which they reporting taking any of these medications.